Prostatic Neoplasms
Conditions
Brief summary
Swelling of the prostate can occur during and after a brachytherapy. This swelling can cause urinary problems ranging from difficulty voiding to urinary retention. The purpose of this study is to investigate whether Mobicox started one week before brachytherapy and then continued afterwards is more effective in reducing the risk of needing a catheter than Mobicox given only afterwards.
Interventions
DRUGMeloxicam
Sponsors
Princess Margaret Hospital, Canada
University Health Network, Toronto
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Eligible to receive prostate brachytherapy as per the Ontario Provincial Guidelines will be eligible for this study (i.e. prostate specific antigen \[PSA\] \< 10, Gleason score \<7, Stage \<= T2a)
Exclusion criteria
* Patients already taking anti-inflammatory drugs * Patients with allergic-type reactions, including asthma and urticaria, to aspirin or nonsteroidal anti-inflammatory agents (see product information)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare 2 schedules of MeloxicamTM given in the peri-operative period to reduce prostate swelling after permanent seed implantation for prostate cancer | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the influence of different timing of MeloxicamTM administration on urinary toxicity and biochemical response after permanent seed implantation for prostate cancer | — |
Countries
Canada
Outcome results
None listed